Everand Logo

Welcome to Everand!

  • STAT

    STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya

    Novo Nordisk announced a plan to spend a whopping $6 billion to expand its manufacturing capacity at its main production site in Denmark.
    by Ed Silverman Nov 10, 2023 1 minute
    Source: Alex Hogan/STAT

    And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far,, , and . And what about you? This may be an opportunity to enjoy the great outdoors before the winter chill sets in. You might want to get a jump on holiday shopping. Or simply take a moment to plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
    Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
    Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.

    Related Books & Audiobooks